Fish oil supplements are among the most widely purchased dietary supplements globally, and the omega-3 fatty acids they provide — EPA and DHA — have one of the more substantial research bases in nutrition science. They've also been the subject of several large, high-profile trials with surprising results that complicated an earlier consensus. Understanding where the evidence stands requires looking at both what the research supports and where earlier enthusiasm outran the data.
What EPA and DHA Are and Why They Matter
Omega-3 fatty acids are a family of polyunsaturated fats. The most biologically active forms are EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), found primarily in fatty fish and seafood. ALA (alpha-linolenic acid) is a plant-derived omega-3 found in flaxseed, chia seeds, and walnuts; humans can convert ALA to EPA and DHA, but the conversion rate is low (roughly 5-10% for EPA, even less for DHA), making ALA a poor substitute for direct EPA and DHA intake.
EPA and DHA are incorporated into cell membranes throughout the body, where they influence membrane fluidity and the function of embedded proteins. They are precursors to specialized pro-resolving mediators (SPMs) — molecules that actively resolve inflammation rather than simply not promoting it. DHA is the predominant structural fat in the brain and retina, essential for normal neurological development and function.
What the Evidence Shows
Cardiovascular outcomes were the original promise of fish oil supplementation, supported by early epidemiological observations of low cardiovascular disease rates in fish-eating populations like the Greenlandic Inuit. The evidence here has become more nuanced.
Early meta-analyses of omega-3 trials were promising. Then the ASCEND and ORIGIN trials in 2018 showed no significant cardiovascular benefit in people with diabetes or other cardiovascular risk factors. The field appeared to be heading toward a negative conclusion.
Then the REDUCE-IT trial, also published in 2018, showed a striking 25% reduction in major adverse cardiovascular events with high-dose EPA (4 grams per day of icosapentaenoic acid, the pharmaceutical form) in people with elevated triglycerides and established cardiovascular disease or diabetes. Critically, REDUCE-IT used a mineral oil placebo that may have inflated the apparent benefit — a significant methodological controversy.
The STRENGTH trial used a different placebo (corn oil) and found no benefit with high-dose omega-3s in a similar population.
The current evidence supports: triglyceride lowering is real and substantial (high-dose omega-3s reduce triglycerides by 15-30%), which is a clinically meaningful lipid effect. Cardiovascular event reduction at standard supplemental doses remains uncertain. High-dose prescription EPA in specific high-risk populations may have benefits, but the evidence is disputed.
Brain health and cognitive function show consistent observational associations — people who eat more fish have lower rates of cognitive decline and Alzheimer's disease. DHA is the dominant structural fat in the brain. Intervention trials in people without diagnosed cognitive impairment have produced mixed results. The evidence is more convincing for DHA's role in normal brain development (supporting supplementation during pregnancy and breastfeeding) than for supplementation improving cognition in otherwise healthy adults.
Depression and mood have been the subject of numerous trials. EPA appears more active than DHA in mood-related effects. A meta-analysis found that supplements with higher EPA:DHA ratios showed consistent antidepressant effects in people with clinical depression. The evidence base for non-clinical populations is weaker.
Anti-inflammatory effects are consistently demonstrated — EPA and DHA reliably reduce circulating inflammatory markers (CRP, IL-6, TNF-α) at sufficient doses.
Practical Guidance
For most people without diagnosed conditions, eating fatty fish two or more times per week — salmon, mackerel, sardines, herring, anchovies — provides approximately 1-2 grams of combined EPA+DHA per week and represents the dietary approach supported by the broadest evidence.
For supplementation, 1-2 grams of combined EPA+DHA per day is the most commonly studied range for general health. Quality matters: fish oil oxidizes readily, and rancid fish oil may have no benefit or possible harm. Buying from reputable manufacturers with third-party testing, storing refrigerated after opening, and checking for fresh smell (quality fish oil should not smell strongly fishy) are reasonable precautions.
For people with high triglycerides, higher doses (2-4 grams per day) show consistent triglyceride-lowering effects and may be worth discussing with a physician.
For vegetarians and vegans, algal oil provides directly bioavailable EPA and DHA derived from the algae at the base of the marine food chain (what fish eat to become rich in omega-3s). It's more expensive than fish oil and available in fewer formulations, but it's the only plant-based source of preformed EPA and DHA.
The omega-3 story is genuinely complicated by recent trial results, and the earlier certainty about cardiovascular benefits has been appropriately revised. What remains: triglyceride lowering works, anti-inflammatory effects are real, and for brain health and mood there are plausible mechanisms and some positive trial data. Eating fatty fish remains the most evidence-consistent approach; supplementation is a reasonable addition for people who don't eat fish regularly.
